nx_drug_pathway.nx

nx_drug_pathway.nx -- GTM SUITE / INVESTIGATIONAL DRUG DEVELOPMENT rung. The lawful route for a substance that has no supplement channel anywhere: develop it as a MEDICINE. This models the phases, the clocks, the money, and the places where siting the work abroad genuinely helps. IT IS NOT A MARKET-ENTRY PROBLEM, IT IS A DEVELOPMENT PROBLEM. "How do I get this to market in another country" has no cheap answer, because no country sells unapproved drugs to consumers -- they license them after evidence. What DOES differ between countries is where you can generate that evidence quickly and cheaply, and that difference is large and legitimate. AUSTRALIA IS THE REAL ANSWER TO "SOMEWHERE ELSE". Under the CTN scheme an early-phase trial is NOTIFIED to the TGA after a human research ethics committee approves it, rather than waiting on a regulator's review clock -- so Phase 1 starts in weeks rather than months. Stack the 43.5% REFUNDABLE R&D tax offset on top and early clinical work lands near a third of the US cost. That is why a great many biotechs run first-in-human in Australia and then take the data to FDA or EMA. It is entirely lawful, well-trodden, and it is the honest version of "go abroad". PRIOR HUMAN DATA IS THE OTHER LEVER, AND IT IS BIGGER. A substance already studied in humans may be able to rely on that record -- 505(b)(2) in the US, a hybrid application in the EU -- instead of repeating the work. That is the difference between a ~$120M full programme and something a fraction of it. It also means two peptides that look alike commercially can be very far apart developmentally: one with published clinical work has an on-ramp, one with mostly rodent data does not. WHAT NO JURISDICTION OFFERS, ENCODED AS A FUNCTION. There is no country where an unapproved drug may be sold to consumers, and a foreign approval does not license a sale into a market that did not grant it. Those are dp_dtc_without_approval_anywhere() and dp_foreign_approval_licenses_export(), both hard 0, so a planner cannot route around them. COSTS ARE ORDER-OF-MAGNITUDE PLANNING FIGURES for a small peptide, in THOUSANDS OF USD; durations in MONTHS. Real programmes vary by an order of magnitude and most fail. dp_estimate_is_indicative() exists so nothing downstream presents these as a budget.